| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership
Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company's ABS-201 (anti-PRLR) program for androgenetic alopecia.
Additionally, Absci now expects to initiate the Phase 1/2a trial for this program in early December, ahead of prior guidance for early 2026, with an interim efficacy readout anticipated in the second half of 2026. The seminar to be hosted on December 11 will feature leading KOLs in the dermatology and hair loss fields, and highlight the clinical trial path, differentiated profile, and market potential of the ABS-201 program.
Posted In: ABSI
